ALPPS ;From human to mice highlighting accelerated and novel mechanisms of liver regeneration

Annals of Surgery

Volumn 260, Issue 5, 2014, Pages 839-847

  Schlegel, Andrea ^a   Lesurtel, Mickael ^a   Melloul, Emmanuel ^a   Limani, Perparim ^a   Tschuor, Christoph ^a   Humar, Bostjan ^a   Clavien, Pierre A ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Alpps; Human to mice; Novel mechanisms of regeneration; Pvl; Transection

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; INTERLEUKIN 6; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ASSOCIATING LIVER PARTITION AND PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL; LIVER REGENERATION; LIVER RESECTION; LIVER WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; CHOLECYSTECTOMY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERTROPHY; KIDNEY; LIGATION; LUNG; PORTAL VEIN; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; SURGERY;

ANIMALS; BIOLOGICAL MARKERS; CHOLECYSTECTOMY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATECTOMY; HUMANS; HYPERTROPHY; KIDNEY; LIGATION; LIVER REGENERATION; LUNG; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; PORTAL VEIN; REAL-TIME POLYMERASE CHAIN REACTION; SPLEEN;

EID: 84921472736     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000949     Document Type: Conference Paper

References (31)

1. Clavien PA, Oberkofler CE, Raptis DA, et al. What is critical for liver surgery and partial liver transplantation: Size or quality? Hepatology. 2010;52:715-729.
2. Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med. 2007;356:1545-1559.
3. Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant. 2005;5:2605-2610.
4. Jaeck D, Oussoultzoglou E, Rosso E, et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004;240:1037-1049; discussion 1049-1051.
5. Schadde E, Ardiles V, Slankamenac K, et al. ALPPS offers a better chance of complete resection in patients with primarily unresec table liver tumors compared to classical staged hepatectomies. World J Surg. 2014;38:1510- 1519.
6. Donati M, Stavrou GA, Oldhafer KJ. Current position of ALPPS in the surgical landscape of CRLM treatment proposals. World J Gastroenterol. 2013;19:6548-6554.
7. Heinrich S, Lang H. Livermetastases from colorectal cancer: Technique of liver resection. J Surg Oncol. 2013;107:579-584.
8. de Santibanes E, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: The "ALPPS" approach. Ann Surg. 2012;255:415-417.
9. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255:405-414.
10. Dokmak S, Belghiti J. Which limits to the "ALPPS" approach? Ann Surg. 2012;256:e6; author reply e16-e17.
11. Nadalin S, Capobianco I, Li J, et al. Indications and Limits for Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS). Lessons learned from 15 cases at a single centre. Z Gastroenterol. 2014;52:35- 42.
12. Tschuor C, Croome KP, Sergeant G, et al. Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion-an extension of the ALPPS approach. Eur J Surg Oncol. 2013;39: 1230-1235.
13. Jain HA, Bharathy KG, Negi SS. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy: Will the morbidity of an additional surgery be outweighed by better patient outcomes in the long-term? Ann Surg. 2012;256:e10; author reply e16-e17.
14. Kokudo N, Shindoh J. How can we safely climb the ALPPS? Updates Surg. 2013;65:175-177.
15. Torres OJ, Fernandes Ede S, Oliveira CV, et al. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): The Brazilian experience. Arq Bras Cir Dig. 2013;26:40-43.
16. Conrad C, Shivathirthan N, Camerlo A, et al. Laparoscopic portal vein ligation with in situ liver split for failed portal vein embolization. Ann Surg. 2012;256:e14-e15; author reply e16-e17.
17. Torres OJ, Moraes-Junior JM, Lima, Lima NC, et al. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): A new approach in liver resections. Arq Bras Cir Dig. 2012;25:290-292.
18. Knoefel WT, Gabor I, Rehders A, et al. In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection. Br J Surg. 2013;100:388-394.
19. Shindoh J, Vauthey JN, Zimmitti G, et al. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg. 2013;217:126-133; discussion 133-134.
20. Aloia TA, Vauthey JN. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): What is gained and what is lost? Ann Surg. 2012;256:e9; author reply e16-e19.
21. Furrer K, Tian Y, Pfammatter T, et al. Selective portal vein embolization and ligation trigger different regenerative responses in the rat liver. Hepatology. 2008;47:1615-1623.
22. Aussilhou B, Lesurtel M, Sauvanet A, et al. Right portal vein ligation is as efficient as portal vein embolization to induce hypertrophy of the left liver remnant. J Gastrointest Surg. 2008;12:297-303.
23. Loos M, Friess H. Is there new hope for patients with marginally resec table liver malignancies. World J Gastrointest Surg. 2012;4:163-165.
24. Balk RA. Systemic inflammatory response syndrome (SIRS): Where did it come from and is it still relevant today? Virulence. 2014;5:20-26.
25. Vincent JL, Opal SM, Marshall JC, et al. Sepsis definitions: Time for change. Lancet. 2013;381:774-775.
26. von Heesen M, Hulser M, Seibert K, et al. Split-liver procedure and inflammatory response: Improvement by pharmacological preconditioning. J Surg Res. 2011;168:e125-e135.
27. Michalopoulos GK. Principles of liver regeneration and growth homeostasis. Compr Physiol. 2013;3:485-513.
28. Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007;213:286-300.
29. Katja B, Hartmut K, Pawel M, et al. The value of immune modulating parameters in predicting the progression from peritonitis to septic shock. Shock. 2001;15:95-100.
30. Martin C, Boisson C, Haccoun M, et al. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med. 1997;25:1813-1819.
31. Palmes D, Spiegel HU. Animal models of liver regeneration. Biomaterials. 2004;25:1601-1611.